![](https://investorshub.advfn.com/uicon/280555.png?cb=1594066301)
Wednesday, April 26, 2023 6:45:59 PM
OpGen’s Subsidiary Curetis Meets All Remaining Key Milestones in R&D Collaboration with FIND
Triggers milestone payment of approximately $0.3 million
ROCKVILLE, Md., April 26, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported today that its German subsidiary Curetis GmbH has met the remaining key milestones under the initial research and development (“R&D”) collaboration agreement with FIND. Following the delivery of a comprehensive milestone report at the end of first quarter of 2023, FIND confirmed that all requirements have been met successfully. Under the recently announced expansion of the collaboration, the originally planned Next Generation Sequencing (“NGS”) strain analysis will be complemented with isolates from other sub-Saharan African countries. Completion of the deliverables triggered a milestone payment of approximately $0.3 million.
The R&D collaboration to date has successfully addressed the development and initial wet-lab testing of a sample-in to result-out Unyvero A30 panel with 33 targets, including fully integrated sample preparation. Multiple Unyvero A30 instrument adaptations were made to optimize for use in the challenging environments of low- and middle- income countries (LMICs). Instrument prototypes have been designed, built and tested for operation in high-dust, extended temperature range and power-out scenarios.
Andreas Boos, Chief Technology Officer at Curetis GmbH commented: “We are excited to have successfully delivered the final milestones from the first phase of our collaboration agreement and look forward to working on the next set of deliverables under the expanded scope of our R&D partnership with FIND.”
Johannes Bacher, Chief Operating Officer of OpGen added: “We believe the successful first phase of our development collaboration puts us in an ideal position towards development of a robust solution optimized for use in LMICs, a goal we would like to pursue during a potential next phase of this collaboration under a new agreement with FIND.”
Dr. Cecilia Ferreyra, Director, FIND AMR Programme remarked that, “We have evaluated the final milestone data from Curetis on the Unyvero A30 and have confirmed that the adapted prototype test meets the quality and accuracy requirements for use in low- and middle-income countries. We look forward to potential continued collaboration to expand testing for blood stream infections in LMIC hospitals so that people can be linked to the care they need as soon as possible.”
About OpGen, Inc.
Recent OPGN News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/08/2024 08:30:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2024 08:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 08:01:21 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 05/30/2024 08:30:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 08:30:33 PM
- OpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-Q • GlobeNewswire Inc. • 05/24/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 08:15:20 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/17/2024 09:02:10 PM
- OpGen Announced 1-for-10 Reverse Stock Split • GlobeNewswire Inc. • 05/16/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:30:23 PM
- OpGen Provides Update on Business Operations and Strategic Opportunities • GlobeNewswire Inc. • 04/29/2024 08:05:00 PM
- OpGen Receives Nasdaq Notice Regarding Delayed Form 10-K • GlobeNewswire Inc. • 04/23/2024 08:15:00 PM
- Shares Rip In Reaction To Activist Investor Becoming CEO • AllPennyStocks.com • 03/26/2024 08:20:00 PM
- OpGen Announces Acquisition of Preferred Stock by David Lazar • GlobeNewswire Inc. • 03/25/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 09:30:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 12:30:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2024 09:30:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 09:58:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:37:15 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/24/2023 05:15:18 AM
- OpGen Reports Third Quarter 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 11/14/2023 09:30:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 11/13/2023 09:59:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2023 09:30:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/26/2023 08:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2023 08:30:09 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM
HealthLynked Expands Telemedicine Nationwide • HLYK • Jul 17, 2024 8:00 AM
Peer To Peer Network aka Mobicard™ Launches AI Investor Chatbot Boosting Engagement & Lead Generation on Ihub • PTOP • Jul 15, 2024 8:30 AM
Greenlite Ventures Announces AI Integration into No Limit Platforms • GRNL • Jul 15, 2024 8:00 AM
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM